Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Human hypoxia inducible factor-1 alpha recombinant adenovirus carrier and uses thereof

A carrier, transcription factor technology, applied in growth factors/inducing factors, applications, recombinant DNA technology, etc.

Inactive Publication Date: 2008-11-19
NANFANG HOSPITAL OF SOUTHERN MEDICAL UNIV
View PDF0 Cites 14 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is no adenovirus-mediated HIF-1α at home and abroad 564 Single mutant, HIF-1α 564 / 402 double mutant, HIF-1α 564 / 803 double mutant and HIF-1α 402 / 564 / 803 According to the reports of triple mutant gene therapy for the above diseases, gene therapy mediated by introducing recombinant adenovirus vector into the coronary artery through cardiac catheterization may be a safe and effective method and has great clinical application value

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Human hypoxia inducible factor-1 alpha recombinant adenovirus carrier and uses thereof
  • Human hypoxia inducible factor-1 alpha recombinant adenovirus carrier and uses thereof
  • Human hypoxia inducible factor-1 alpha recombinant adenovirus carrier and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0131] Example 1 Construction of Hypoxia Inducible Factor 1α Wild Type and Its Mutant Recombinant Adenoviral Vectors

[0132] 1.1 Materials and methods

[0133] 1.1.1 Instruments and equipment

[0134] 2500E CO 2 Incubator American NuAire Company

[0135] Ultra-clean workbench Suzhou Scientific Instrument Co., Ltd.

[0136] CK40-F200 Inverted Phase Contrast Microscope Japan OLYMPUS Company

[0137]Cell culture plate American Corning company

[0138] UNIVERSAL 32R / 16R low temperature centrifuge Germany Hettich company

[0139] Ultra-high speed centrifuge US BECKMEN company

[0140] Far Infrared Stainless Steel Oven Suzhou Scientific Instruments Co., Ltd.

[0141] FR-800 PCR instrument American BioMetra company

[0142] Stabilized voltage and current electrophoresis instrument Bio-Rad, USA

[0143] GeneGenius Gel Imaging Analysis System Gene Corporation

[0144] Smart spcet TM 3000 Nucleic Acid / Protein Quantification American BIO-RAD Company

[0145] instrument

[0...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a mutant hypoxia inducible factor 1alpha, coded nucleic acid of the mutant hypoxia inducible factor 1alpha, a carrier containing wild coded nucleic acid of the mutant hypoxia inducible factor 1alpha, in particular to a recombinant adenovirus carrier and a drug composition containing the mutant hypoxia inducible factor 1 alpha, the coded nucleic acid and the carriers. The mutant protein, the nucleic acid, the carriers and the drug composition can be used to treat ischemic diseases, such as coronary heart disease, peripheral arterial ischemic vascular diseases, intermittent claudication and so on.

Description

field of invention [0001] The present invention relates to the field of gene therapy. More specifically, the present invention relates to mutant hypoxia-inducible factor 1α, its coding gene, a vector containing hypoxia-inducible factor 1α wild type and its mutant gene, especially a recombinant adenovirus vector, the construction of the recombinant adenovirus vector and They are used as therapeutic agents for coronary heart disease, peripheral arterial ischemic vascular disease, intermittent claudication and the like. Background technique [0002] Coronary heart disease is one of the major diseases that threaten human health. The treatment measures currently mainly include conventional drug therapy, coronary intervention (percutaneous coronary intervention, PCI) and coronary artery bypass grafting (coronary artery bypass grafting, CABG). Revascularization is required, so other methods must be sought. In recent years, with the advancement of molecular biology techniques, ge...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K14/475C12N15/11C12N15/861C12N15/63A61K38/17A61P9/10C12N1/15C12N1/19C12N1/21C12N5/10C12N15/12
Inventor 吴平生王月刚刘城陈娓傅锐斌郭寿贵谢宜军童铠胡英芳赖艳娴
Owner NANFANG HOSPITAL OF SOUTHERN MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com